A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children

Vaccine

Volumn 28, Issue 3, 2010, Pages 744-753

  Knuf, M ^a   Kieninger Baum, D ^a   Habermehl, P ^a   Muttonen, P ^b   Maurer, H ^c   Vink, P ^d   Poolman, J ^d   Boutriau, D ^d  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Ginzkeypl 10/2 ^*  (Austria)

^c Ginzkeypl 10/2   (Austria)

^d GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Bactericidal activity; Conjugate vaccine; Tetravalent meningococcal vaccine

Indexed keywords

DIPHTHERIA TOXOID CRM197; MENCEVAX; MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANOREXIA; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOGENICITY; INFANT; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE SWELLING; IRRITABILITY; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; MUSCLE HYPOTONIA; NEISSERIA MENINGITIDIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SKIN REDNESS; VACCINATION; VOMITING;

ANTIBODIES, BACTERIAL; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; TETANUS TOXOID; VACCINES, CONJUGATE;

EID: 71249129860     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.064     Document Type: Article

References (44)

1. Rosenstein N.E., Perkins B.A., Stephens D.S., Popovic T., and Hughes J.M. Meningococcal disease. N Engl J Med 344 18 (2001) 1378-1388
2. Anderson M.S., Glode M.P., and Smith A.L. Meningococcal disease. In: Feigin R.D., and Cherry J.D. (Eds). Textbook of pediatric infectious diseases (1998), WB Saunders, Philadelphia 1143-1156
3. Sáfadi M.A., and Barros A.P. Meningococcal conjugate vaccines: efficacy and new combinations. J Pediatr (Rio J) 82 July (Suppl. 3) (2006) S35-S44
4. Harrison L.H., Pass M.A., Mendelsohn A.B., Egri M., Rosenstein N.E., Bustamante A., et al. Invasive meningococcal disease in adolescents and young adults. JAMA 286 6 (2001) 694-699
5. Pollard A.J. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 23 December (Suppl. 12) (2004) S274-S279
6. Campagne G., Schuchat A., Djibo S., Ousséini A., Cissé L., and Chippaux J.P. Epidemiology of bacterial meningitis in Niamey, Niger, 1981-96. Bull World Health Organ 77 6 (1999) 499-508
7. Greenwood B. Manson lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 93 4 (1999) 341-353
8. World Health Organization. Control of epidemic meningococcal disease. WHO practical guidelines. 2nd ed. (2002), World Health Organization, Geneva WHO/EMC/BAC/98.3
9. Koroleva I., Beloshitskij G., Spirihina L., Zacroeve I., Mironov K., Shipulin G., et al. Incidence of invasive meningococcal disease in Russia [abstract]. European Monitoring Group on Meningococci. Rome, Italy, May 30-June 1 (2007)
10. European Union Invasive Bacterial Infections Surveillance Network. Invasive Neisseria meningitidis in Europe; 2006. [Accessed 17.6.2009]. Available at http://www.euibis.org/neisseria.htm.
11. Connolly M., and Noah N. Is group C meningococcal disease increasing in Europe? A report of surveillance of meningococcal infection in Europe 1993-1996. Epidemiol Infect 122 1 (1999) 41-49
12. Australian Meningococcal Surveillance Programme. Annual report of the Australian Meningococcal Surveillance Programme, 2006. Commun Dis Intell 31 June (2) (2007) 185-194
13. Jódar L., Feavers I.M., Salisbury D., and Granoff D.M. Development of vaccines against meningococcal disease. Lancet 359 April (9316) (2002) 1499-1508
14. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance. [Accessed 19.7.2008]. Available at: http://www.cdc.gov/ncidod/dbmd/abcs/survreports.htm.
15. Canada Communable Disease Report; 2007:33(10). [Accessed 25.1.2008]. Available at http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/07vol33/dr3310ea.html.
16. Vazquez J.A., Adab R., Brandileone M.C., Chanto G., Gabastou J.M., Gorla M.C.O., et al. Molecular characterization of invasive serogroup Y Neisseria meningitides strains isolated in Latin America region [abstract]. International pathogenic neisseria conference. Rotterdam, The Netherlands, 7-12 September (2008)
17. Lingappa J.R., Al-Rabeah A.M., Hajjeh R., Mustafa T., Fatani A., Al-Bassam T., et al. Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg Infect Dis 9 6 (2003) 665-671
18. Traoré Y., Njanpop-Lafourcade B.M., Adjogble K.L., Lourd M., Yaro S., Nacro B., et al. The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005. Clin Infect Dis 43 7 (2006) 817-822
19. World Health Organization Geneva. Enhanced surveillance of epidemic meningococcal meningitis in Africa: a three-year experience. Wkly Epidemiol Rec 80 37 (2005) 313-320
20. Aguilera J.F., Perrocheau A., Meffre C., Hahné S., and W135 Working Group. Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000. Emerg Infect Dis 8 8 (2002) 761-767
21. Boisier P., Nicolas P., Djibo S., Taha M.K., Jeanne I., Maïnassara H.B., et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 44 5 (2007) 657-663
22. Empfehlungen der STIKO am Robert-Koch-Institut. Epidemiol Bull (2008) 30
23. Miller E., Salisbury D., and Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20 (2001) S58-S67
24. de Greeff S.C., de Melker H.E., Spanjaard L., Schouls L.M., and van Derende A. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J 25 January (1) (2006) 79-80
25. Larrauri A., Cano R., García M., and Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 23 July (32) (2005) 4097-4100
26. De Wals P., Deceuninck G., Boulianne N., and De Serres G. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA 292 November (20) (2004) 2491-2494
27. Booy R., Jelfs J., El Bashir H., and Nissen M.D. Impact of meningococcal C conjugate vaccine use in Australia. Med J Aust 186 3 (2007) 108-109
28. Bilukha O.O., and Rosenstein N. National center for infectious diseases, centers for disease control and prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 54 RR-7 (2005) 1-21
29. ®. Prescribing information. Swiftwater, PA: Sanofi Pasteur Inc. [Accessed 15.10.2008]. Available at http://www.menactra.com/prescribing_information.html.
30. Rennels M., King Jr. J., Ryall R., Papa T., and Froeschle J. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meningogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J 23 May (5) (2004) 429-435
31. Pace D., and Pollard A.J. Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines. Arch Dis Child 92 10 (2007) 909-915
32. Safety and immunogenicity of a quadrivalent meningococcal tetanus protein conjugate vaccine in toddlers. [Accessed 19.8.2009]. Available at www. clinical trials.gov NCT00631995.
33. Ostergaard L., Lebacq E., Poolman J., Maechler G., and Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 27 1 (2009) 161-168
34. Maslanka S.E., Gheesling L.L., Libutti D.E., Donaldson K.B., Harakeh H.S., Dykes J.K., et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol 4 2 (1997) 156-167
35. Borrow R., Andrews N., Goldblatt D., and Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immunol 69 (2001) 1568-1573
36. Borrow R., Balmer P., and Miller E. Meningococcal surrogates of protection - serum bactericidal antibody activity. Vaccine 23 March (17-18) (2005) 2222-2227
37. Centers for disease control prevention (CDC). Inadvertent misadministration of meningococcal conjugate vaccine-United States June-August 2005. MMWR Recomm Rep 55 37 (2006) 1016-1017
38. Keyserling H., Papa T., Koranyi K., Ryall R., Bassily E., Bybel A., et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 159 10 (2005) 907-913
39. Jackson L.A., Baxter R., Reisinger K., Karsten A., Shah J., Bedell L., et al. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis 49 1 (2009) e1-e10
40. Snape M.D., Perrett K.P., Ford K.J., John T.M., Pace D., Yu L.M., et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 299 2 (2008) 173-184
41. Trotter C.L., Andrews N.J., Kaczmarski E.B., Miller E., and Ramsay M.E. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364 9431 (2004) 365-367
42. De Wals P., Coudeville L., Trottier P., Chevat C., Erickson L.J., and Nguyen V.H. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis. Vaccine 25 29 (2007) 5433-5440
43. Centers for disease control prevention. Notice to Readers: revised recommendations of the advisory committee on immunization practices to vaccinate all persons aged 11-18 years with meningococcal conjugate vaccine. MMWR Recomm Rep 56 31 (2007) 794-795
44. Centers for disease control prevention. Notice to Readers: recommendation from the advisory committee on immunization practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MCV4) in children aged 2-10 years at increased risk for invasive meningococcal disease. MMWR Recomm Rep 56 48 (2007) 1265-1266